Quality of Sexual Life in Hyperandrogenic Women Treated with an Oral Contraceptive Containing Chlormadinone Acetate
Corresponding Author
Salvatore Caruso MD
Research Group for Sexology, Department of Microbiological Science and Gynaecological Science, University of Catania, Catania, Italy;
Salvatore Caruso, MD, Microbiological and Gynaecological Science, University of Catania, Via Torre del Vescovo Catania, 95124, Italy. Tel: +390957435509; Fax: +39095312001; E-mail: [email protected]Search for more papers by this authorSalvatore Rugolo MD
Ultrasound Service, Department of Microbiological Science and Gynaecological Science, University of Catania, Catania, Italy
Search for more papers by this authorCarmela Agnello MD
Research Group for Sexology, Department of Microbiological Science and Gynaecological Science, University of Catania, Catania, Italy;
Search for more papers by this authorMattea Romano MD
Research Group for Sexology, Department of Microbiological Science and Gynaecological Science, University of Catania, Catania, Italy;
Search for more papers by this authorAntonio Cianci MD
Research Group for Sexology, Department of Microbiological Science and Gynaecological Science, University of Catania, Catania, Italy;
Search for more papers by this authorCorresponding Author
Salvatore Caruso MD
Research Group for Sexology, Department of Microbiological Science and Gynaecological Science, University of Catania, Catania, Italy;
Salvatore Caruso, MD, Microbiological and Gynaecological Science, University of Catania, Via Torre del Vescovo Catania, 95124, Italy. Tel: +390957435509; Fax: +39095312001; E-mail: [email protected]Search for more papers by this authorSalvatore Rugolo MD
Ultrasound Service, Department of Microbiological Science and Gynaecological Science, University of Catania, Catania, Italy
Search for more papers by this authorCarmela Agnello MD
Research Group for Sexology, Department of Microbiological Science and Gynaecological Science, University of Catania, Catania, Italy;
Search for more papers by this authorMattea Romano MD
Research Group for Sexology, Department of Microbiological Science and Gynaecological Science, University of Catania, Catania, Italy;
Search for more papers by this authorAntonio Cianci MD
Research Group for Sexology, Department of Microbiological Science and Gynaecological Science, University of Catania, Catania, Italy;
Search for more papers by this authorABSTRACT
Introduction. Hyperandrogenism produces change in quality of life of women.
Aim. To prespectively determine the changes of the sexual behaviour of hyperandrogenic women using an oral contraceptive containing 30 µg ethinylestradiol and 2 mg chlormadinone acetate (EE/CMA).
Methods. Seventy-two volunteer women (age range, 18–32 years), with moderate to severe hirsutim and acne were treated with EE/CMA for 9 cycles.
Main Outcomes Measure(s). To assess hirsutism, the Ferriman-Gallwey (F-G) scoring system was used. Serum FSH, LH, estradiol, total and free testosterone, DHEAS, androstenedione, and SHBG levels were measured at baseline and at the 9th cycle of pill intake. The Short Personal Experience Questionnaire (SPEQ), the Short Form-36 (SF-36), and a visual analog scales questionnaires were used to assess the QoL, at baseline and after 3, 6 and 9 cycles of pill use.
Result(s). A reduction of 65% and 81% in the total mean F-G score was observed after the 6th cycle and the 9th cycle, respectively. The serum Androstenedione, and total and free testosterone levels decreased, and SHBG levels increased after the 9th cycle (p < 0.05). The SF-36 score was higher after 6 (p < 0.05) 9 cycles (p < 0.001) with respect to baseline. Frequency of sexual intercourse and of orgasm by intercourse increased, and the frequency of masturbation decreased during the 6th (p < 0.05) and the 9th cycle (p < 0.001).
Conclusion(s). The EE/CMA pill has anti-androgenic properties reducing the anti-aesthetic effect of hyperandrogenism and improving female sexual and social self-esteem. Caruso S, Rugolo S, Agnello C, Romano M, and Cianci A. Quality of sexual life in hyperandrogenic women treated with an oral contraceptive containing chlormadinone acetate. J Sex Med 2009;6:3376–3384.
References
- 1 Homburg R. What is polycystic ovarian syndrome?—A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome. Hum Reprod 2002; 17: 2495–9.
- 2 Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745–9.
- 3 Franks S. Assessment and management of anovulatory infertility in polycystic ovary syndrome. Endocrinol Metab Clin North Am 2003; 32: 639–51.
- 4 Hahn S, Bering van Halteren W, Kimmig R, Mann K, Gärtner R, Janssen OE. Diagnostic procedures in polycystic ovary syndrome. J Lab Med 2003; 27: 53–9.
- 5 Kitzinger C, Willmott J. The thief of womanhood”: Women's experience of polycystic ovarian syndrome. Soc Sci Med 2002; 54: 349–61.
- 6 Elsenbruch S, Benson S, Hahn S, Tan S, Mann K, Pleger K, Kimmig R, Janssen OE. Determinants of emotional distress in women with polycystic ovary syndrome. Hum Reprod 2006; 21: 1092–9.
- 7 Tan S, Hahn S, Benson S, Janssen OE, Dietz T, Kimmig R, Hesse-Hussain J, Mann K, Schedlowski M, Arck PC, Elsenbruch S. Psychological implications of infertility in women with polycystic ovary syndrome. Hum Reprod 2008; 23: 2064–71.
- 8 Månsson M, Holte J, Landin-Wilhelmsen K, Dahlgren E, Johansson A, Landén M. Women with polycystic ovary syndrome are often depressed or anxious—A case control study. Psychoneuroendocrinology 2008; 33: 1132–8.
- 9 Hahn S, Janssen OE, Tan S, Pleger K, Mann K, Schedlowski M, Kimmig R, Benson S, Balamitsa E, Elsenbruch S. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol 2005; 153: 853–60.
- 10 Bernard L, Ferriday D, Guenther N, Strauss B, Balen AH, Dye L. Quality of life and psychological well being in polycystic ovary syndrome. Hum Repr 2007; 22: 2279–86.
- 11 McCook JG, Reame NE, Thatcher SS. Health-related quality of life issues in women with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs 2005; 34: 12–20.
- 12 Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. J Clin Endocrinol Metab 2008; 93: 1408–11.
- 13 Elsenbruch S, Hahn S, Kowalsky D, Offner AH, Chedlowski M, Mann K, Janssen OE. Quality of life, psychosocial well-being and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 5801–7.
- 14 Trent ME, Rich M, Austin SB, Gordon CM. Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome. Implications for quality of life. J Pediatr Adolesc Gynecol 2003; 16: 33–7.
- 15 Hahn S, Benson S, Elsenbruch S, Pleger K, Tan S, Mann K, Schedlowski M, Van Halteren WB, Kimmig R, Janssen OE. Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress and sexuality. Hum Reprod 2006; 21: 1925–34.
- 16 Weiner CL, Primeau M, Ehrmann DA. Androgen and mood dysfunction in women: Comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med 2004; 66: 356–62.
- 17 Dronavalli S, Ehrmann DA. Pharmacologic therapy of polycystic ovary syndrome. Clin Obstet Gynecol 2007; 50: 244–54.
- 18 Moghetti P, Toscano V. Treatment of hirsutism and acne in hyperandrogenism. Best Pract Res Clin Endocrinol Metab 2006; 20: 221–34.
- 19 Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 2002; 77: 919–27.
- 20 Vrbikova J, Dvorakova K, Hill M, Starka L. Weight change and androgen levels during contraceptive treatment of women affected by polycystic ovary. Endocr Regul 2006; 40: 119–23.
- 21 Escobar Morreale HF. Polycystic ovary syndrome: Treatment strategies and management. Expert Opin Pharmacother 2008; 9: 2995–3008.
- 22 Rosenfield RL. What every physician should know about polycystic ovary syndrome. Dermatol Ther 2008; 21: 354–61.
- 23 Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care 2007; 12: 30–5.
- 24 Sabatini R, Orsini G, Cagiano R, Loverro G. Noncontraceptive benefits of two oral contraceptives with antiandrogenic properties among adolescents. Contraception 2007; 76: 342–7.
- 25 Schramm G, Steffens D. A 12-month evaluation of the CMA containing oral contraceptive Belara: Efficacy, tolerability and antiandrogenic properties. Contraception 2003; 67: 305–12.
- 26 Kerscher M, Reuther T, Bayrhammer J, Schramm G. Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups: An open-label, single-centre, phase IV study. Clin Drug Investig 2008; 28: 703–11.
- 27 Zahradnik HP, Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)—An open-label, prospective, noncontrolled, office-based Phase III study. Contraception 2008; 77: 337–43.
- 28 Raudrat D, Rabe T. Progestogens with anti-androgenic properties. Drugs 2003; 63: 463–92.
- 29 The Rotterdam ESHRE/ARSM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensusion diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–7.
- 30 Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440–7.
- 31 Carmina E, Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovary syndrome? Fertil Steril 1999; 71: 319–22.
- 32 Basson R, Berman J, Burnet A, Derogatis L, Ferguson D, Fourcroy J, Goldstein I, Graziottin A, Heiman J, Laan E. Definition and classification of female sexual dysfunction: Second report of the international consensus development conference on female sexual dysfunction. J Urol 2000; 163: 888–93.
- 33 Ware JE, Kosinski M, Gandek BG, Aaronson NK, Apolone G, Bech P, Brazier J, Bullinger M, Kaasa S, Leplège A, Prieto L, Sullivan M. The factor structure of the SF-36 Health Survey in 10 countries: Results from the International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol 1998; 51: 1159–65.
- 34 Dennerstein L, Lehert P, Duldey E. Short scale to measure female sexuality: Adapted from McCoy Female Sexuality Questionnaire. J Sex Marital Ther 2001; 27: 339–51.
- 35 Battaglia C, Nappi RE, Mancini F, Cianciosi A, Persico N, Busacchi P, Facchinetti F, Sisti G. PCOS, sexuality, and clitoral vascularisation: A pilot study. J Sex Med 2008; 5: 2886–94.
- 36 Caruso S, Agnello C, Intelisano G, Farina M, Di Mari L, Sparacino L, Cianci A. Prospective study on sexual behavior of women using 30 microg ethinylestradiol and 3 mg drospirenone oral contraceptive. Contraception 2005; 72: 19–23.
- 37 Caruso S, Agnello C, Intelisano G, Farina M, Di Mari L, Cianci A. Sexual behavior of women taking low-dose oral contraceptive containing 15 µg ethinylestradiol/60 µg gestodene. Contraception 2004; 269: 237–40.
- 38 Stuckey BG. Female sexual function and dysfunction in the reproductive years: The influence of endogenous and exogenous sex hormones. J Sex Med 2008; 5: 2282–90.
- 39 Jones GL, Hall JM, Balen AH, Ledger WL. Health-related quality of life measurement in women with polycystic ovary syndrome: A systematic review. Hum Reprod Update 2008; 14: 15–25.
- 40 Janssen ON, Hahn S, Tan S, Benson S, Elsenbruch S. Mood and sexual function in polycystic ovary syndrome. Semin Reprod Med 2008; 26: 45–52.
- 41 Porcile A, Gallardo E. Long-term treratment of hirsutism: Desogestrel compared with cyproterone acetate in oral contraceptives. Fertil Steril 1991; 55: 877–81.
- 42 Bhathena RK. Therapeutic options in the polycyctic ovary syndrome. J Obstet Gynecol 2007; 27: 123–9.
- 43 Falsetti L, Gambera A, Plato C, Legrenzi L. Management of hirsutism. Am J Clin Dermat 2000; 1: 89–99.
- 44 Balen AH. The current understanding of polycystic ovary syndrome. Obstet Gynaecol 2004; 666: 74.
- 45 Lanham MS, Lebovic DI, Domino SE. Contemporary medical therapy for polycystic ovary syndrome. Int J Gynaecol Obstet 2006; 95: 236–41.
- 46 Ajossa S, Guerriero S, Paoletti AM, Orrù M, Melis GB. The treatment of polycystic ovary syndrome. Minerva Ginecol 2004; 56: 15–26.
